A citation-based method for searching scientific literature

Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang, Limeng Chen. Diabetes Obes Metab 2018
Times Cited: 107



Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. N Engl J Med 2015
Times Cited: 5013




List of shared articles



Times cited

Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
Victor Okunrintemi, Basem M Mishriky, James R Powell, Doyle M Cummings. Diabetes Obes Metab 2021
8


Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Austin G Stack, David Han, Ronald Goldwater, Susanne Johansson, Nalina Dronamraju, Jan Oscarsson, Eva Johnsson, Joanna Parkinson, Fredrik Erlandsson. J Clin Endocrinol Metab 2021
4

Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
Hongtao Yu, Weifeng Tang, Peter J Greasley, Robert C Penland, David W Boulton, K Melissa Hallow. J Clin Pharmacol 2021
3

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
3

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
11

SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich, Vladimir Jakovljevic. Heart Fail Rev 2021
6

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu. Front Cardiovasc Med 2021
2

The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
Ziyu Meng, Xiaohuan Liu, Ting Li, Ting Fang, Ying Cheng, Liping Han, Bei Sun, Liming Chen. Int Immunopharmacol 2021
6


Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.
Kasper B Kristensen, Daniel P Henriksen, Jesper Hallas, Anton PottegĂ„rd, Lars C Lund. Diabetologia 2021
0

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
9



Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, Pia Clara Pafundi, Raffaele Galiero, Alfredo Caturano, Elisabetta Moscarella, Felice Gragnano, Teresa Salvatore, Luca Rinaldi,[...]. Int J Mol Sci 2021
3

Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights.
Asma Gulab, Ricardo Torres, Jerald Pelayo, Kevin Bryan Lo, Anum Shahzad, Supriya Pradhan, Janani Rangaswami. Expert Rev Cardiovasc Ther 2021
0

Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, Bruno Tassone, Roberta Pujia, Marco Ricchio, Raffaele Serra, Angela Sciacqua, Ashour Michael, Michele Andreucci,[...]. Front Med (Lausanne) 2021
0

Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
Utkarsh Ojha, Lenisse Reyes, Florence Eyenga, Diane Oumbe, Justyna Watkowska, Henock Saint-Jacques. Am J Cardiovasc Drugs 2021
2

Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.
Lei Xiao, Xin Nie, Yanyan Cheng, Nanping Wang. Cardiovasc Drugs Ther 2021
1

Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
Victor Chien-Chia Wu, Yan-Rong Li, Chao-Yung Wang. Int J Mol Sci 2021
0

Bexagliflozin for type 2 diabetes: an overview of the data.
Omar Azzam, Revathy Carnagarin, Leslie Marisol Lugo-Gavidia, Janis Nolde, Vance B Matthews, Markus P Schlaich. Expert Opin Pharmacother 2021
0

The Role of SGLT2 Inhibitors in Vascular Aging.
Le Liu, Yu-Qing Ni, Jun-Kun Zhan, You-Shuo Liu. Aging Dis 2021
1

A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease.
Lucia Del Vecchio, Angelo Beretta, Carlo Jovane, Silvia Peiti, Simonetta Genovesi. Drugs 2021
1

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Sossalla. Curr Heart Fail Rep 2021
0